Evidence map›Paper›PMID 28865768›Full record

ArticleJournal of cystic fibrosis : official journal of the European Cystic Fibrosis Society2017

A first step to STOP cystic fibrosis exacerbations.

Pierre-Régis Burgel, David W Reid, Shawn D Aaron

Abstract readEditorialComment
PubMed Publisher
In one paragraph

Article in Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Correlates of FEV₁ deficit in pulmonary exacerbations of cystic fibrosis and associated clinical outcomes.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2026
    Trial
  2. Trial
  3. Trial
  4. STOP Using Corticosteroids in Cystic Fibrosis Pulmonary Exacerbations.Annals of the American Thoracic Society · 2024
    Article
  5. Article
  6. Article
  7. Review
  8. Procalcitonin predicts the severity of cystic fibrosis pulmonary exacerbations and readmissions in adult patients: a prospective cohort study.Journal of investigative medicine : the official publication of the American Federation for Clinical Research · 2020
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Pierre-Régis BurgelCochin Hospital, Assistance Publique-Hôpitaux de Paris and Paris Descartes University, Sorbonne Paris Cité, Paris, France. Electronic address: pierre-regis.burgel@aphp.fr.
David W ReidDepartment of Thoracic Medicine, The Prince Charles Hospital, Brisbane, Queensland, Australia; QIMR Berghofer Medical Research Institute; School of Medicine, University of Queensland, Brisbane, Queensland, Australia.
Shawn D AaronThe Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Anti-Bacterial AgentsCystic FibrosisAdministration, IntravenousForced Expiratory VolumeHumansLungAnti-Bacterial Agents

Identifiers

PMID28865768

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.